HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

KBP-5074

Also Known As:

4-((3S,3aS)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo(3,4-f)quinolin-2-yl)-2-chlorobenzonitrile

Networked: 6 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - KBP-5074: 6
  - Piperidines: 17
    - KBP-5074: 6
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - KBP-5074: 6

Experts

1.	Bakris, George: 3 articles (10/2021 - 01/2020)
2.	Pitt, Bertram: 3 articles (10/2021 - 01/2020)
3.	Yang, Y Fred: 3 articles (01/2021 - 01/2020)
4.	Benn, Vincent: 2 articles (01/2021 - 01/2021)
5.	Agarwal, Rajiv: 1 article (01/2022)
6.	Georgianos, Panagiotis I: 1 article (01/2022)
7.	Jaisser, Frederic: 1 article (10/2021)
8.	Al Dhaybi, Omar: 1 article (01/2021)
9.	BLOCK-CKD Study Group: 1 article (01/2021)
10.	Bakris, George L: 1 article (01/2021)

Related Diseases

1.	Cardiovascular Diseases (Cardiovascular Disease) 10/01/2021 - "In a randomized, double-blind, placebo-controlled phase 2b trial, the novel nonsteroidal MRA KBP-5074 demonstrated clinical efficacy and safety in treating RH in stage 3B/4 CKD and offers a potential new treatment option in this population at high risk for cardiovascular disease (CVD) and CKD progression."
2.	Albuminuria 01/01/2021 - "The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury."
3.	Hypertension (High Blood Pressure) 10/01/2021 - "An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension." 01/01/2022 - "In the BLOCK-CKD trial, the investigational nonsteroidal mineralocorticoid-receptor-antagonist (MRA) KBP-5074 lowered office SBP by 7-10 mmHg relative to placebo at 84 days with a minimal risk of hyperkalaemia in patients with advanced CKD and uncontrolled hypertension. " 01/01/2020 - "KBP-5074 is a nonsteroidal mineralocorticoid receptor antagonist under investigation for the treatment of treatment-resistant and uncontrolled hypertension in patients with moderate-to-severe CKD. " 01/01/2020 - "BLOCK-CKD is a phase 2, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of KBP-5074, on top of current therapy, in patients with stage 3B/4 CKD (estimated glomerular filtration rate ≥15 and ≤44 mL/[min·1.73 m2]) and resistant hypertension (trough cuff seated systolic blood pressure ≥140 mm Hg, despite treatment with maximally tolerated doses of 2 or more antihypertensive medicines with complementary mechanisms). "
4.	Chronic Renal Insufficiency 01/01/2021 - "Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study." 10/01/2021 - "An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension."
5.	Hyperkalemia 10/01/2021 - "KBP-5074 is a novel non-steroidal MRA that addresses the unmet need of treating RH in the CKD population without hyperkalemia. " 01/01/2020 - "BLOCK-CKD will determine whether the addition of KBP-5074 will effectively lower blood pressure without an increased risk of hyperkalemia in patients who are not candidates for steroidal mineralocorticoid receptor antagonists due to advanced CKD. "

Related Drugs and Biologics

1.	Mineralocorticoid Receptor Antagonists
2.	Mineralocorticoids
3.	Eplerenone (Inspra)
4.	Antihypertensive Agents (Antihypertensives)
5.	finerenone

Related Therapies and Procedures

1.	Therapeutics